Leidos Holdings Total Cost of Revenue increased by 4.9% to $3.64B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.3%, from $3.49B to $3.64B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 4.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.85B | $2.95B | $2.94B | $2.98B | $2.98B | $3.06B | $3.10B | $3.18B | $3.20B | $3.27B | $3.33B | $3.39B | $3.34B | $3.43B | $3.43B | $3.67B | $3.49B | $3.47B | $3.65B | $3.47B | $3.64B |
| QoQ Change | — | +3.6% | -0.3% | +1.4% | -0.0% | +2.6% | +1.2% | +2.6% | +0.9% | +2.1% | +1.9% | +1.5% | -1.4% | +2.7% | +0.0% | +7.1% | -5.0% | -0.5% | +5.1% | -4.9% | +4.9% |
| YoY Change | — | — | — | — | +4.7% | +3.7% | +5.2% | +6.5% | +7.4% | +6.9% | +7.7% | +6.6% | +4.2% | +4.8% | +2.8% | +8.5% | +4.5% | +1.3% | +6.4% | -5.6% | +4.3% |